2 completed. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
Follow Refractory Ependymoma: new trials by email Literature Review of Refractory Ependymoma trials Research Report on Refractory Ependymoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study - Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma | Phase 2 | Completed | National Cancer Institute (NCI) | 23 | 2018-08-13 | 2026-04-03 |
| Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) Olaparib - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 6 | 2017-09-14 | 2024-12-11 |
Ependymoma (2) · Familial ependymoma (2) · Glioma (2) · Hepatoblastoma (2) · Histiocytosis, Langerhans-Cell (2) · Lymphoma, Non-Hodgkin (2) · Medulloblastoma (2) · Neuroblastoma (2) · Neuroectodermal Tumors, Primitive, Peripheral (2) · Osteosarcoma (2) · Rhabdoid Tumor (2) · Rhabdomyosarcoma (2) · Sarcoma (2) · Wilms Tumor (2) · Central Nervous System Neoplasms (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Genetic Diseases, Inborn (2) · Hemic and Lymphatic Diseases (2) · Histiocytosis (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Kidney Diseases (2) · Kidney Neoplasms (2) · Lung Diseases (2) · Lung Diseases, Interstitial (2) · Lymphatic Diseases (2) · Lymphoma (2) · Lymphoproliferative Disorders (2)
olaparib (1) · palbociclib (1)
National Cancer Institute (NCI) (2)
Puerto Rico (2) · United States (2)
Julia Glade-Bender (1) · Rajen Mody (1)
PMID 31401903, PMID 38815151, PMID 39298716
U10CA180886 (2)